Ovarian squamous cell carcinoma

Summary

Ovarian squamous cell carcinoma (MONDO:0003494) is a cancer and 2 clinical trials. Top therapeutic interventions include ipilimumab. A subtype of ovarian squamous cell neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ovarian squamous cell carcinoma
Mondo ID	MONDO:0003494
EFO	EFO:1000432
DOID	DOID:5531
NCIT	C40093
UMLS	C2019443
MedGen	384474
GARD	0023529
Anatomy (UBERON)	UBERON:0000992
Is cancer (heuristic)	yes

Also known as: ovarian squamous cell cancer · ovarian squamous cell carcinoma · ovary squamous cell carcinoma

Data availability: 2 cell lines.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › ovarian epithelial tumor › ovarian squamous cell neoplasm › ovarian squamous cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02834013	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT05737199	PHASE2	ACTIVE_NOT_RECRUITING	Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IPILIMUMAB	4	1